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IN PRACTICE
Burkitt’s lymphoma (BL), the most common 
childhood cancer in sub-Saharan Africa, 
occurs mainly in areas with holo-endemic 
malaria.[1] Young children with haemoglobin 
(Hb) AS (sickle cell trait) are largely protected 
against severe Plasmodium falciparum mala-
ria.[2} The prevalence of AS in the Northwest 
region of Cameroon, a holo-endemic malaria 
area, is between 10% and 30%.[2] The annual 
incidence of BL between 2003 and 2010 was 
2.58/100 000 children <15 years of age, and the 
monthly average of malaria cases was 10 938 in 
the dry season and 11 499 in the rainy season.[3] 
It is hypothesised that the AS trait lowers the 
risk of developing BL.
One hundred Nigerian Yoruba children 
with BL had a significantly lower incidence 
of the AS genotype than hospital controls. No 
difference in frequency of AS was, however, 
subsequently observed between 306 Kenyan 
children with BL and age-, ethnically and geo-
graphically matched controls.[4,5] 
We observed an AS incidence of 7% in 
167 BL patients treated in Cameroon,[6] and 
subsequently conducted a prospective study 
in surviving BL patients resident in the 
Northwest region.
Methods
Seventy-nine BL patients in the Northwest 
region of Cameroon were visited at home, 
where a nearest-neighbour control of the 
same tribe, age and sex was identified. One 
parent of a patient with BL refused consent.
An ethylenediaminetetra-acetic acid (EDTA) 
venous blood sample was obtained from the 
index patients and controls, and paper 
electrophoresis was performed at pH 8.9 
in boric and trisaminomethane (TRIS) 
buffer. Institutional review board appro-
val and informed parental consent were 
obtained. 
Results 
The 79 BL patients included 41 girls and 
38 boys aged 4 - 17 (mean 9.9) years. 
Controls had a similar age and gender 
distribution. Four (5.13%) BL patients had 
AS compared with 11 (14.10%) controls 
(χ2 (df=1)=3.74, p=0.052; Fisher’s exact, 
one-tailed, p=0.050) (Table 1).  
Discussion 
The validity of the Nigerian study[4] was later 
questioned because controls were not from 
the same tribe, region and village. It is not 
clear whether controls in the Kenyan study[5] 
were carefully matched for age and if they 
were indeed nearest-neighbour controls. 
This is of critical importance because of 
large differences in the distribution of the 
AS gene. 
Conclusion
The relatively small number of patients 
studied limits the statistical significance of our 
findings. This study of confirmed BL patients 
and very well-matched controls did, however, 
demonstrate that AS carriers in Cameroon 
probably have a reduced risk of developing BL. 
Further studies in this regard are justified. 
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Contradictory findings have been reported from Africa with regard to the risk of developing Burkitt’s lymphoma (BL) in sickle cell trait (AS) 
carriers. Haemoglobin electrophoresis was performed in 78 BL patients in the Northwest region of Cameroon, and in 78 nearest-neighbour 
controls of the same age, sex and tribe from the same village. AS was confirmed in 4 of 78 (5.13%) BL patients and in 11 of 78 (14.10%) 
controls (χ2, p=0.052; Fisher’s exact, one-tailed, p=0.050). Sickle cell trait carriers had a marginal statistically reduced risk of developing BL. 
S Afr Med J 2016;106(7):686. DOI:10.7196/SAMJ.2016.v106i7.10693
Table 1. Observed frequencies of 
Hb AA and Hb AS
Subjects Hb AA Hb AS Total
Patients, n 74 4 78
Patients, % 94.87 5.13
Controls, n 67 11 78
Controls, % 85.9 14.10
Total 141 15 156
χ2 (df=1)=3.74, p=0.052; Fisher’s exact, one-tailed, 
p=0.050.
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